SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-098576
Filing Date
2024-08-19
Accepted
2024-08-19 16:30:27
Documents
60
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aktx-20240630.htm   iXBRL 10-Q 1987659
2 EX-10.3 aktx-ex10_3.htm EX-10.3 62679
3 EX-10.5 aktx-ex10_5.htm EX-10.5 43012
4 EX-31.1 aktx-ex31_1.htm EX-31.1 14657
5 EX-31.2 aktx-ex31_2.htm EX-31.2 14636
6 EX-32.1 aktx-ex32_1.htm EX-32.1 10052
7 EX-32.2 aktx-ex32_2.htm EX-32.2 9571
  Complete submission text file 0000950170-24-098576.txt   8284679

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20240630.xsd EX-101.SCH 1423264
63 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20240630_htm.xml XML 1303571
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-36288 | Film No.: 241221018
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)